If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

  • There is currently no data for N4P

Director/PDMR Shareholding

10 Nov 2017 16:04

RNS Number : 2255W
N4 Pharma PLC
10 November 2017
 

10th November 2017

 

N4 Pharma plc (the "Company")

 

Notification of Transaction by Directors/PDMRs

 

The Company was notified on 10th November 2017 that a Person Discharging Management Responsibilities ("PDMR"), had purchased shares in the Company as set out below. Following this purchase, Nigel Theobald now has a total beneficial interest in 12,255,233 Ordinary Shares, representing 16.4% of the issued share capital of the Company.

The Company's share capital consists of 74,714,285 Ordinary Shares with voting rights.

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

 

Name

 

Nigel Theobald

2

Reason for the notification

 

a)

 

Position/status

CEO and Director

 

b)

 

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

N4 Pharma Plc

 

b)

 

LEI

213800I841D2RKMFK955

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument Identification code

Oridinary shares BGP 0.0004

 

ISIN code GB00BYW8QM32

 

 

b)

 

Nature of the transaction

Direct purchase of shares

 

c)

 

Price(s) and volume(s)

 

Price

volume

£0.07925

56,656

d)

Aggregated information

- Aggregated price

- Aggregated volume

- Aggregated total

n/a

 

e)

 

Date of the transaction

10th November 2017

 

f)

 

Place of the transaction

London Stock Exchange, AIM

g)

Additional Information

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEAKFEFEDXFFF
Date   Source Headline
23rd May 202412:19 pmRNSResult of AGM
29th Apr 202410:59 amRNSPosting of Annual Report & Notice of AGM
26th Apr 20247:00 amRNSN4 Pharma Webinar on SRI Collaboration
25th Apr 20247:38 amRNSCollaboration Agreement with SRI International Inc
23rd Apr 20247:00 amRNSFinal Results
18th Apr 20247:00 amRNSOral Delivery Update
4th Mar 20243:13 pmRNSHolding(s) in Company
29th Feb 20247:00 amRNSHolding(s) in Company
15th Feb 20247:00 amRNSin-vitro siRNA update
19th Jan 20247:00 amRNSPatent Grant
18th Jan 202410:15 amRNSHolding(s) in Company
16th Jan 20247:00 amRNSNanogenics Update
8th Jan 20244:24 pmRNSHolding(s) in Company
8th Jan 20247:00 amRNSAAV Viral Vector Update
18th Dec 20237:00 amRNSOral Delivery Update
7th Dec 202311:28 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSNuvec® R&D and Strategy Update
30th Nov 20239:00 amRNSN4 Pharma Launches New Interactive Investor Hub
31st Oct 20237:00 amRNSTotal Voting Rights
9th Oct 20237:00 amRNSInvestor Presentation via Investor Meet Company
3rd Oct 20238:15 amRNSHolding(s) in Company
2nd Oct 20237:00 amRNSInvestor Presentation
28th Sep 20237:00 amRNSAcquisition of Controlling Interest in Nanogenics
12th Sep 20237:00 amRNSInterim Results
25th Jul 20237:00 amRNSPatent Grant and Board Change
27th Jun 20237:00 amRNSGrant Award for Professor Chengzhong Yu
25th Apr 20237:00 amRNSsiRNA update
18th Apr 20237:00 amRNSsiRNA update
3rd Apr 20232:11 pmRNSResult of AGM
9th Mar 20237:00 amRNSPosting of Annual Report & Notice of AGM
9th Mar 20237:00 amRNSFinal Results
14th Feb 20234:40 pmRNSSecond Price Monitoring Extn
14th Feb 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20232:05 pmRNSSecond Price Monitoring Extn
17th Jan 20232:00 pmRNSPrice Monitoring Extension
17th Jan 202311:05 amRNSSecond Price Monitoring Extn
17th Jan 202311:00 amRNSPrice Monitoring Extension
17th Jan 20239:05 amRNSSecond Price Monitoring Extn
17th Jan 20239:00 amRNSPrice Monitoring Extension
17th Jan 20237:00 amRNSOral application update
30th Nov 20225:28 pmRNSHolding(s) in Company
30th Nov 20227:00 amRNSTotal Voting Rights
25th Nov 20222:49 pmRNSHolding(s) in Company
22nd Nov 202210:50 amRNSResult of Broker Offer and Total Voting Rights
18th Nov 20227:01 amRNSBroker Offer to raise a maximum of £1 million
18th Nov 20227:00 amRNSPlacing to raise £1million and Broker Offer
1st Nov 20227:00 amRNSPatent filing update
4th Oct 20227:00 amRNSDouble siRNA Testing Update
29th Sep 20227:00 amRNSInterim Results
14th Sep 20227:00 amRNSOperational Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.